Device Trial Radar · NCT07929857
Effectiveness and Safety of Cellbooster Hair in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
55
Planned (sponsor's estimate)
Start
Jan 27, 2027
Primary completion
Oct 31, 2027
Study completion Oct 31, 2027
Sponsor
- Lead sponsor
- SuisselleNot on our public-company list
- Sponsor type
- Industry
- First posted
- Nov 10, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Cellbooster® Hair (CBH) is a class III medical device, CE marked, HA-based injectable using the patented CHAC Technology. It consists of stabilized Hyaluronic Acid 18mg (6mg/ml) with Amino Acids and Vitamins, and minerals (zinc, copper). The medical device is designed for strengthening hair follicles, improving hair growth and microcirculation. It restores scalp skin structure and provides hair fiber restructuring. The device is a resorbable injectable implant for preventing and treating various scalp and hair problems linked to hormonal imbalance, psoriasis, seborrhea, stress, nutrition and trace elements deficiencies, such as: hair loss, hair breakage, scalp dehydration, dandruff, premature graying. The device improves microcirculation, restores scalp skin structure and other qualities, provides hair fiber restructuring after physical and/or chemical damage, such as: hair dying, permanent wave, sun, dryer. The current post-market clinical investigation aims to evaluate the efficacy and safety of CBH in the scalp of subjects. For this purpose, healthy subjects with signs of hair loss will receive a 6-session treatment spaced every 2 weeks and will be followed-up over 130 days after the initial injection session. Objective measurements of scalp function and hair characteristics parameters will be performed allowing to assess hair density, hair diameter, hair structure, scalp hydration, scalp barrier function and thickness and having illustrative pictures. Subjective clinical improvement will be evaluated with clinical scoring, as well as subject and investigator satisfaction degrees. The safety of the injections will be assessed by collecting the Injection Site Reactions (ISRs) and Adverse Events (AEs).
Conditions
- Hair and Scalp Health
Interventions
Scalp booster injection (CBH)Device
Eligible subjects will receive six intradermal treatment sessions with CBH, administered at 14-day intervals on Days 0, 14, 28, 42, 56 and 70. CellBooster® Hair (CBH) Class III medical device Composition non-crosslinked Sodium Hyaluronate 18 mg; * amino acids (Arginine, Cysteine, Glutamine, Glycine, Lysine); * vitamins (Niacin, Pantothenic Acid, Pyridoxine, Biotin, Cyanocobalamin, Rutin); * Copper Gluconate, Zinc Carbonate; * phosphate buffer pH 6.8-7.6 q.s.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline of hair density (total number of hair in the studied zone) at Day 130 evaluated by Phototrichogram (PTG) analysisTime frame: Day 130
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Eurofins Dermscan Pharmascan
Aix-en-Provence, France
Eurofins Dermscan Pharmascan
Villeurbanne, France
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.